Protagenic Therapeutics Inc. and Phytanix Bio Inc. have announced a business combination to form a new entity, Phytanix, Inc. This merger, through an all-stock transaction, aims to consolidate their pipelines, focusing on stress-related and CNS disorders. The combined portfolio will include six drug candidates, with five in preclinical stages and one at the clinical stage. Key assets will target obesity, metabolic disorders, and various CNS conditions. The merger will see Protagenic Therapeutics' shareholders owning approximately 35% of the new entity, while Phytanix Bio's shareholders will own about 65%.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagenic Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1029131) on May 19, 2025, and is solely responsible for the information contained therein.